Sintilimab Combined With Albumin-Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced
Yufan Tang1, Boquan Zhou1, Bingbing Wen1
1Department of General Surgery The 940th Hospital, Joint Logistics Support Force of Chinese People's Liberation Army Lanzhou China.
Clinical Case Reports
|September 4, 2026
Abstract:
For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD-1 inhibitor with albumin-bound paclitaxel and S-1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with favorable performance status and MDT-supported indications, as pathological complete remission appears to be attainable in this context.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.